10-Q: Spero Therapeutics Reports Q2 Loss, Tebipenem HBr Advances

Spero Therapeutics reported a reduced net loss in Q2 2025, driven by increased collaboration revenue from GSK and reduced R&D expenses following the successful early halt of its pivotal Phase 3 tebipenem HBr trial, while facing an ongoing SEC investigation and pipeline reprioritization.

Summary

• Spero Therapeutics reported a net loss of $1.7 million for Q2 2025, a significant improvement from a $17.9 million net loss in Q2 2024.
• Total revenues increased to $14.2 million in Q2 2025 from $10.2 million in Q2 2024, primarily due to a $5.9 million increase in collaboration revenue from GSK.
• Research and development expenses decreased by $13.1 million to $10.7 million in Q2 2025, largely due to the early cessation of the PIVOT-PO trial for tebipenem HBr and the suspension/discontinuation of other programs.
• The pivotal Phase 3 PIVOT-PO trial for tebipenem HBr met its primary endpoint and was stopped early for efficacy in May 2025, with GSK planning an NDA submission in the second half of 2025.
• Development of SPR720 (oral formulation) was suspended in October 2024 due to an interim analysis not meeting its primary endpoint and dose-limiting safety issues, including reversible grade 3 hepatotoxicity.
• Development of SPR206 was discontinued in March 2025, leading to the termination of the NIAID contract in April 2025.
• The company received a $23.8 million milestone payment from GSK in Q1 2025 and the final $23.8 million payment in Q3 2025.
• Spero Therapeutics expects its cash and cash equivalents of $31.2 million as of June 30, 2025, combined with GSK milestone payments, to fund operations into 2028.
• The company is subject to an ongoing SEC investigation and received a Wells Notice in January 2025 regarding public disclosures related to tebipenem HBr from March 2022 to May 2022.
• The company regained compliance with Nasdaq's $1.00 bid price requirement in June 2025 after receiving a deficiency letter in February 2025.

Sentiment

Score: 7

Explanation: The successful early completion of the pivotal Phase 3 trial for tebipenem HBr and the extended cash runway are significant positives, indicating strong progress for the company's lead asset. However, the complete discontinuation/suspension of other pipeline programs (SPR206, SPR720) and the ongoing SEC investigation introduce substantial concentration risk and legal uncertainty, tempering overall sentiment. The improved financial loss is also a positive, but the increased cash burn from operations is a concern.

Positives

• Net loss significantly improved to $1.7 million in Q2 2025 from $17.9 million in Q2 2024, and to $15.6 million for the six months ended June 30, 2025, from $30.5 million in the prior year period.
• Total revenues increased to $14.2 million in Q2 2025 and $20.1 million for the six months ended June 30, 2025, driven by higher collaboration revenue from GSK.
• The pivotal Phase 3 PIVOT-PO trial for tebipenem HBr met its primary endpoint and was stopped early for efficacy in May 2025, indicating positive clinical results.
• GSK plans to submit the New Drug Application (NDA) for tebipenem HBr in the second half of 2025, signaling progress towards potential commercialization.
• The company received a $23.8 million development milestone payment from GSK in Q1 2025 and the final $23.8 million payment in Q3 2025, strengthening liquidity.
• The cash runway is projected to extend into 2028, providing financial stability for the near to medium term.
• The company successfully regained compliance with Nasdaq's minimum bid price requirement in June 2025.

Negatives

• Cash and cash equivalents decreased significantly to $31.2 million as of June 30, 2025, from $52.9 million at December 31, 2024.
• Net cash used in operating activities increased to $21.7 million for the six months ended June 30, 2025, compared to $12.8 million in the prior year period, indicating higher cash burn.
• Development of SPR720 in its oral formulation was suspended in October 2024 due to a lack of efficacy and dose-limiting safety issues (reversible grade 3 hepatotoxicity).
• Development of SPR206 was discontinued in March 2025, leading to the termination of the NIAID contract and loss of associated funding.
• The company has an accumulated deficit of $475.2 million as of June 30, 2025, reflecting a history of significant losses.
• General and administrative expenses increased by $1.3 million for the six months ended June 30, 2025, partly due to retention program costs and executive severance.
• Grant revenue decreased significantly to $3.2 million for the six months ended June 30, 2025, from $9.2 million in the prior year period, primarily due to reduced BARDA funding and NIAID contract termination.

Risks

• Business and prospects are substantially dependent on the tebipenem HBr program and the collaboration with GSK following the suspension of SPR720 and discontinuation of SPR206.
• Ability to realize the value of tebipenem HBr depends on obtaining FDA approval, and any requirements imposed as part of approval may impact commercialization attractiveness.
• Analyses of preliminary or interim data from clinical studies may change as more patient data become available and are subject to audit and verification procedures.
• Serious adverse events or undesirable side effects of product candidates may be identified during development or after approval, potentially delaying or preventing regulatory approval or limiting commercial potential.
• Even if a product candidate obtains regulatory approval, it may not achieve sufficient market acceptance by physicians, patients, hospitals, and third-party payors.
• Inability to establish sales, marketing, and distribution capabilities or enter into agreements with third parties could hinder commercialization success.
• Substantial competition from other pharmaceutical and biotechnology companies could adversely affect operating results.
• Continued history of losses and expectation of substantial future losses; inability to obtain additional capital could force delays or elimination of product development programs.
• Failure to achieve milestones triggering payments in license and collaboration agreements with third parties.
• Reliance on third parties for manufacturing preclinical and clinical supplies increases risk of insufficient quantities or unacceptable costs.
• Failure to comply with obligations in in-license or out-license agreements could result in loss of important rights.
• Government funding for programs adds complexity and may impose requirements that increase commercialization and production costs.
• Inability to obtain and maintain sufficient patent protection or if patent scope is not broad enough, competitors could commercialize similar technologies.
• Failure to enforce registered trademarks or secure registration of pending trademark applications could adversely affect the business.
• Delays in obtaining required regulatory approvals would materially impair the ability to commercialize product candidates and generate revenue.
• The price of common stock has been and may continue to be volatile, potentially resulting in a decline in value for stockholders.
• An ongoing SEC investigation and Wells Notice contemplating civil enforcement action could have a material adverse effect on business, financial condition, results of operations, prospects, and/or stock price.
• Past failure to maintain Nasdaq listing requirements and potential future failure could negatively affect stock price, liquidity, and ability to raise capital.
• Unstable global economic and political conditions, including interest rate volatility, inflation, credit market instability, and geopolitical conflicts, could adversely affect business and ability to raise capital.
• Broad discretion in the use of cash reserves, which may not be used effectively.
• Reduced disclosure requirements as a smaller reporting company may make common stock less attractive to investors.
• Increased costs of operating as a public company and management time devoted to compliance initiatives.
• Failure to maintain effective internal controls could affect financial statement accuracy and stock price.
• Significant portion of total outstanding shares may be sold into the market at any time, causing stock price decline.
• No anticipated cash dividends; stockholders must rely on capital appreciation.
• Provisions in corporate charter documents and Delaware law could make an acquisition more difficult.
• Potential involvement in securities litigation could divert management attention and harm the business.

Future Outlook

The company expects to continue incurring significant expenses and operating losses for the foreseeable future. Based on current cash, cash equivalents, and earned non-contingent development milestone payments from GSK, the company believes its cash runway will be sufficient to fund operating expenses and capital expenditure requirements into 2028. Beyond this period, substantial additional funding will be required, which may be sought through equity offerings, debt financings, collaborations, or government funding. The company plans to prioritize finalizing Phase 3 clinical trial activities for tebipenem HBr under the GSK License Agreement. The impact of new tax legislation (OBBBA) and ongoing litigation related to the Inflation Reduction Act's drug pricing program are being evaluated.

Management Comments

• We believe this re-prioritized strategic focus is the best way to optimize our financial and other resources to advance our goal of developing and commercializing product candidates to address the unmet need for solutions to antibiotic resistant pathogens.
• GSK plans to work with U.S. regulatory authorities to include the data as part of a filing in the second half of 2025.
• Full results will be submitted for presentation at an upcoming scientific meeting and for publication in a peer-reviewed journal.
• We expect to continue to incur significant expenses and operating losses for at least the next year.
• Based on our cash and cash equivalents as of June 30, 2025, together with earned and non-contingent development milestone payments from GSK, including the final payment under the GSK License Agreement of $23.8 million received in the third quarter of 2025, and the decrease in clinical expense as a result of the PIVOT-PO Phase 3 trial for tebipenem HBr stopping early for efficacy following positive interim analysis results, we believe that our cash runway will be sufficient to fund our operating expenses and required capital expenditures into 2028.
• During this period, we plan to prioritize finalizing the Phase 3 clinical trial activities for tebipenem HBr under our GSK License Agreement.
• We will not generate revenue from product sales unless and until we successfully complete clinical development and obtain regulatory approval for our product candidates.
• We continue to cooperate with the SEC, have engaged in further dialogue with the Staff and maintains that the Company’s disclosures were appropriate.

Industry Context

The biopharmaceutical industry is highly competitive, with significant R&D costs and regulatory hurdles. Spero Therapeutics' focus on multi-drug resistant (MDR) bacterial infections addresses a high unmet medical need, particularly with tebipenem HBr as a potential first oral carbapenem for cUTIs. The discontinuation of other pipeline assets (SPR720, SPR206) indicates a strategic shift towards a more focused, de-risked approach, concentrating resources on the most promising candidate. This also reflects the high failure rate in drug development, especially for earlier-stage programs. The industry is also navigating evolving regulatory landscapes, including new diversity requirements for clinical trials and ongoing debates over drug pricing and PBM practices, which could impact future commercialization and profitability.

Comparison to Industry Standards

• Tebipenem HBr's successful Phase 3 trial for cUTI, including pyelonephritis, positions it as a potential first broad-spectrum oral carbapenem, which could offer a significant advantage over existing intravenous (IV) treatments like Avycaz (ceftazidime-avibactam) from Allergan plc and Pfizer, Zerbaxa (ceftolozane-tazobactam) from Merck & Co., and imipenem/cilastatin, by potentially enabling outpatient treatment and reducing healthcare costs.
• The early halt of the PIVOT-PO trial for efficacy is a strong positive indicator, comparable to successful outcomes seen in other late-stage trials where clear efficacy signals allow for early termination, potentially accelerating regulatory review and reducing overall trial costs.
• The suspension of SPR720 development due to lack of sufficient separation from placebo and dose-limiting hepatotoxicity is a common challenge in drug development, where many promising candidates fail in later stages despite initial promise. This is not uncommon in the highly risky NTM-PD space, where effective oral treatments are scarce.
• The discontinuation of SPR206, an IV-administered product, aligns with a broader industry trend of companies streamlining pipelines to focus on core strengths and most viable assets, especially for smaller biopharmaceutical firms with limited resources. Competitors in the IV Gram-negative space include products like Fetroja (cefiderocol) from Shionogi & Co. Ltd. and Xerava (eravacycline) from Innoviva, Inc.
• The company's reliance on third-party manufacturers for clinical and commercial supply is standard practice in the biopharmaceutical industry, but it exposes them to supply chain risks, as seen with other companies facing disruptions due to global macroeconomic events.

Management Changes

Corporate Governance

Legal Proceedings

• Two putative securities class action lawsuits (Richard S. Germond v. Spero Therapeutics, Inc., et al. and Kashif Memon v. Spero Therapeutics, Inc., et al.) were consolidated and subsequently dismissed in their entirety by court order on September 30, 2024, with the case closed on October 28, 2024.
• Two stockholder derivative actions (Marti v. Mahadevia, et al. and Heil v. Mahadevia, et al.) were voluntarily dismissed by the plaintiffs on March 31, 2025, and March 20, 2025, respectively.
• The company received a Wells Notice from the SEC staff on January 9, 2025, indicating a preliminary determination to recommend civil enforcement action against the company, its former CEO, and former CFO related to public disclosures concerning tebipenem HBr from March 31, 2022, to May 3, 2022.
• The SEC action, if authorized, could seek injunctions, cease-and-desist orders, civil monetary penalties, disgorgement, or officer/director bars.
• The company is cooperating with the SEC and maintains its disclosures were appropriate, but the process is expensive and disruptive, with an uncertain outcome.

Related Party Transactions

• Collaboration revenue from GlaxoSmithKline Intellectual Property (No. 3) Limited (GSK), a related party, increased to $11.8 million in Q2 2025 from $5.9 million in Q2 2024, and to $16.9 million for the six months ended June 30, 2025, from $10.0 million in the prior year period.
• The company received a $23.8 million milestone payment from GSK in Q1 2025 and the final $23.8 million payment in Q3 2025 under the GSK License Agreement.
• A significant financing component of $0.4 million (Q2 2025) and $0.7 million (six months ended June 30, 2025) related to the GSK License Agreement was recognized as interest income.

Stakeholder Impact

• **Shareholders**: Potential for increased value due to positive tebipenem HBr clinical trial results and progress towards NDA submission. However, dilution risk from future capital raises, stock price volatility, and uncertainty from the ongoing SEC investigation could negatively impact shareholder value.
• **Employees**: Workforce reduction in October 2024 impacted approximately 39% of employees. Retention awards were approved for remaining non-executive and executive employees to ensure continuity and focus on key programs. Management changes, including the CEO transition, could affect employee morale and stability.
• **Customers (future)**: If approved, tebipenem HBr could offer a new oral treatment option for cUTIs, potentially benefiting patients with limited oral options and healthcare providers seeking alternatives to IV antibiotics.
• **Suppliers/Creditors**: Increased cash burn from operations and reliance on future capital raises could pose risks, though the extended cash runway into 2028 provides some stability. Dependence on third-party manufacturers for drug supply creates supply chain risks.
• **Regulatory Authorities**: The company is actively engaged with the FDA for tebipenem HBr and is cooperating with the SEC regarding the Wells Notice, indicating ongoing regulatory scrutiny and compliance efforts.

Next Steps

• GSK plans to submit the New Drug Application (NDA) for tebipenem HBr to the U.S. Food and Drug Administration (FDA) in the second half of 2025.
• Full results from the PIVOT-PO trial will be submitted for presentation at an upcoming scientific meeting and for publication in a peer-reviewed journal.
• The company is currently determining next steps for SPR720 after suspending its oral formulation development.
• The company will continue to cooperate with the SEC regarding the Wells Notice and engage in further dialogue with the Staff.
• The company will require additional funding beyond its current cash runway into 2028 and plans to seek capital through various financing mechanisms.
• The company is evaluating the impact of the One Big Beautiful Bill Act (OBBBA) on its consolidated financial statements.

Key Dates

Recommendation

The successful Phase 3 trial for tebipenem HBr is a significant positive, de-risking the lead asset and extending the cash runway. This provides a clear path to potential FDA submission and commercialization through the GSK partnership. However, the company has significantly narrowed its pipeline, discontinuing SPR206 and suspending SPR720, making it highly dependent on tebipenem HBr's success. The ongoing SEC investigation and Wells Notice introduce substantial legal and reputational risk, with potential for significant penalties. While the clinical news is strong, the concentrated pipeline and legal overhang warrant a 'hold' recommendation, advising investors to await further clarity on the SEC proceedings and the tebipenem HBr NDA outcome before making more aggressive investment decisions.

Keywords

Biopharmaceutical, Clinical-stage, Antibiotics, Tebipenem HBr, cUTI, Complicated Urinary Tract Infections, Phase 3 Trial, FDA Approval, GSK Collaboration, Drug Development, SEC Investigation, SPR720, SPR206, Orphan Drug, Nasdaq Compliance, Biotechnology, Infectious Diseases, Drug Resistance